Skip to content

Translational Research in Identifying Molecular Mechanisms for Rectal Cancer Metastasis

Translational Research in Identifying Molecular Mechanisms for Rectal Cancer Metastasis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02979795
Enrollment
50
Registered
2016-12-02
Start date
2016-11-30
Completion date
2020-12-31
Last updated
2016-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer, Chemoradiation

Brief summary

Rectal cancer, comprised of 30% of overall colorectal cancer cohort, is one of the leading cancers of Taiwan. In patients with advanced disease, the standard of care is concurrent chemoradiotherapy (CCRT) before surgery. After CCRT, the abscopal effect, a phenomenon that localized radiation not only destroys local tumor but also inhibits the growth of tumor at the remote site, has been observed. This effect is believed to be associated with tumor immune response. In addition, other immune checkpoint molecules, such as Programmed cell death-1(PD-1), Programmed cell death ligand-1 (PD-L1), and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), have been reported associated with therapeutic outcome. However, after CCRT, more than 50% of patients were still either having persistent disease or developed distant metastasis. To improve therapeutic outcome of patients with rectal cancer, this project, thus, aims at exploring the evolution of factors that may affect the abscopal effect and immune checkpoint functions in tissues and in blood before and after CCRT.

Detailed description

For most patients, preoperative chemoradiotherapy results in clinically tumor regression, but the degree of response varies among patients. There are approximately 40-60% of LARC patients treated with CCRT achieve some degree of pathologic response. However, there is yet an effective method before the commencement of CCRT that can predict how patients will respond to CCRT and can subsequently render better survival. Identify patents who will benefit most from CCRT is crucial not only in lowering treatment-related morbidity and sustaining local control but also to improve survival rate in LARC.

Interventions

Preoperative chemoradiotherapy. 2.5 Gray/fraction (Total in 45-54 Gray)

Sponsors

China Medical University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Rectal cancer patients in China Medical University Hospital (Age limit: 20 yrs and older)

Exclusion criteria

* Pregnancy, Disabilities

Design outcomes

Primary

MeasureTime frameDescription
Tumor regression ratewithin 8 weeks after completion of chemoradiotherapycomplete tumor regression rate(TRG) with tumor regression graded at at surgical resection at 8 weeks after completion of chemoradiotherapy

Secondary

MeasureTime frame
Disease free survival5 year
Overall survival5 year
Local recurrence5 year
Distant metastasis5 year

Countries

Taiwan

Contacts

Primary ContactKan Sun Clifford Chao, MD
D94032@mail.cmuh.org.tw886422052121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026